cysonic.....its just a business aspect that I have. I fully agree with the bonuses and they are integral to business as Wim points out to meet milestones. That being said, if the remaining ANDA's are now of little value or because dynamics have changed and competition worsened due to the delay over the past 5 years. you are saying its OK to pay around 1 million per approval and then it not be commercialized?
I just think any good company need to always be reevaluating their market place. selling horse saddles a hundred years ago made sense. would you still think its OK to pay bonuses for coming up with new improved horse saddles if the mode of transportation is now automobiles? when IPCI put out those ANDA's there was a different market place. now things changed. I am giving them the benfit of the doubt that they can find a partner for Glucophage. but if after a few months we see nothing and we find out they gave out another bonus for its approval as we did with Keppra which still remains commercialized, I say its time the company re-evaluate the remaining pending ones.
by all means feel free to disagree LOL. I just hate to pay out more money and then we get say 3 more approvals and there they sit. its just my opinion. the longer we go without a deal for Glucophage the more I am inclined to say our money lies with the ones which are partnered and then any future bonuses should be paid upon commercialization. not just approval. or be tiered. 25% upon approval and 75% upon commercialization.
News 
Market Data 
Discover 
